Cervical Ripening Drugs Market, 2012 to 2023
Market Outline: Cervical Ripening Drugs Market
Cervical ripening is defined as the softening of cervix prior to onset of labor contractions and it is necessary for the cervical dilation and passage of fetus. Cervix softens, thins, dilates, and relaxes in response to the uterine contractions and allows the cervix to easily pass over the fetal part during labor. Cervical ripening drugs are used before the induction of labor for the dilatation of cervix. The ripening of cervix is associated with the reduced collagen fiber strength, decrease in collagen fiber alignment, and diminished the tensile strength of extracellular cervical matrix. The common techniques used for the cervical ripening are mechanical interventions such as insertion of cervical catheters and dilators and application of cervical ripening agents such as prostaglandins.
Market Dynamics: Cervical Ripening Drugs Market
Growing usage of cervical ripening drugs before the induction of labor, rise in R&D activities for the innovation of newer drugs, increase in awareness about cervical ripening drugs in developed and developing countries, low cost of drugs, and government initiations for improving the baby deliveries are anticipated to fuel the cervical ripening drugs market over the forecast period. However, stringent regulatory policies for product approval, adverse effects associated with the cervical ripening drugs, and alternative procedures for the childbirth are expected to hinder the growth of surgical ripening drugs market over the forecast timeframe.
Market Scope: Cervical Ripening Drugs Market
Cervical ripening drugs market is segmented on the basis of drug type, route of administration, distribution channel, and region
Based on the drug type, market is segmented into the following:
Prostaglandins
Oxytocin
Progesterone Receptor Antagonists
Relaxin
Estrogen
Others
Based on the route of administration, market is segmented into the following:
Oral
Intravenous
Vaginal
Based on the distribution channel, market is segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Others
Market Summary: Cervical Ripening Drugs Market
Cervical ripening drugs market is projected to grow at a significant rate with increase in the usage of cervical ripening drugs prior to the induction of labor. Moreover, acquisitions and mergers, product approvals, and product launchings are the key strategies adopted by market players to generate increased revenue in cervical ripening drugs market. For instance, in February 2012, Ferring Pharmaceuticals acquired Cytokine PharmaSciences Inc. and the acquisition includes manufacturing assets of Cervidil (Dinoprostone) in U.S. and Canada.
Regional Analysis: Cervical Ripening Drugs Market
Geographically, global cervical ripening drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America cervical ripening drugs market growth driven by increase in the R&D for the innovation of newer drugs and high awareness about the cervical ripening drugs among the physicians. Europe cervical ripening drugs market has a lucrative growth owing to high adoption of cervical ripening drugs, launching of newer drugs by the market players. Asia Pacific cervical ripening drugs market has significant share owing to rise in number of female population, government initiations for the baby birth, and increase in the using of cervical ripening drugs before the induction of labor are propel the market. Middle East and Africa cervical ripening drugs market has a prominent share owing to increase in the number of births and rise in awareness about the cervical ripening drugs are in the region.
Competition Assessment: Cervical Ripening Drugs Market
Some of the players in the global cervical ripening drugs market include:
Ferring B.V. (Switzerland)
Azanta A/S (Denmark)
Novartis AG (Switzerland)
GlaxoSmithKline plc (U.K.)
AstraZeneca plc (U.K.)
Pfizer, Inc. (U.S.)
Bayer AG (Germany)
Notable Market Developments: Cervical Ripening Drugs Market
In February 2016, Azanta A/S filed marketing authorization application in Nordic countries for Angusta (Misoprostol), which is indicated in induction of labor
Cervical ripening is defined as the softening of cervix prior to onset of labor contractions and it is necessary for the cervical dilation and passage of fetus. Cervix softens, thins, dilates, and relaxes in response to the uterine contractions and allows the cervix to easily pass over the fetal part during labor. Cervical ripening drugs are used before the induction of labor for the dilatation of cervix. The ripening of cervix is associated with the reduced collagen fiber strength, decrease in collagen fiber alignment, and diminished the tensile strength of extracellular cervical matrix. The common techniques used for the cervical ripening are mechanical interventions such as insertion of cervical catheters and dilators and application of cervical ripening agents such as prostaglandins.
Market Dynamics: Cervical Ripening Drugs Market
Growing usage of cervical ripening drugs before the induction of labor, rise in R&D activities for the innovation of newer drugs, increase in awareness about cervical ripening drugs in developed and developing countries, low cost of drugs, and government initiations for improving the baby deliveries are anticipated to fuel the cervical ripening drugs market over the forecast period. However, stringent regulatory policies for product approval, adverse effects associated with the cervical ripening drugs, and alternative procedures for the childbirth are expected to hinder the growth of surgical ripening drugs market over the forecast timeframe.
Market Scope: Cervical Ripening Drugs Market
Cervical ripening drugs market is segmented on the basis of drug type, route of administration, distribution channel, and region
Based on the drug type, market is segmented into the following:
Prostaglandins
Oxytocin
Progesterone Receptor Antagonists
Relaxin
Estrogen
Others
Based on the route of administration, market is segmented into the following:
Oral
Intravenous
Vaginal
Based on the distribution channel, market is segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Others
Market Summary: Cervical Ripening Drugs Market
Cervical ripening drugs market is projected to grow at a significant rate with increase in the usage of cervical ripening drugs prior to the induction of labor. Moreover, acquisitions and mergers, product approvals, and product launchings are the key strategies adopted by market players to generate increased revenue in cervical ripening drugs market. For instance, in February 2012, Ferring Pharmaceuticals acquired Cytokine PharmaSciences Inc. and the acquisition includes manufacturing assets of Cervidil (Dinoprostone) in U.S. and Canada.
Regional Analysis: Cervical Ripening Drugs Market
Geographically, global cervical ripening drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America cervical ripening drugs market growth driven by increase in the R&D for the innovation of newer drugs and high awareness about the cervical ripening drugs among the physicians. Europe cervical ripening drugs market has a lucrative growth owing to high adoption of cervical ripening drugs, launching of newer drugs by the market players. Asia Pacific cervical ripening drugs market has significant share owing to rise in number of female population, government initiations for the baby birth, and increase in the using of cervical ripening drugs before the induction of labor are propel the market. Middle East and Africa cervical ripening drugs market has a prominent share owing to increase in the number of births and rise in awareness about the cervical ripening drugs are in the region.
Competition Assessment: Cervical Ripening Drugs Market
Some of the players in the global cervical ripening drugs market include:
Ferring B.V. (Switzerland)
Azanta A/S (Denmark)
Novartis AG (Switzerland)
GlaxoSmithKline plc (U.K.)
AstraZeneca plc (U.K.)
Pfizer, Inc. (U.S.)
Bayer AG (Germany)
Notable Market Developments: Cervical Ripening Drugs Market
In February 2016, Azanta A/S filed marketing authorization application in Nordic countries for Angusta (Misoprostol), which is indicated in induction of labor
1. EXECUTIVE SUMMARY
2. GLOBAL CERVICAL RIPENING DRUGS MARKET INTRODUCTION
2.1. Global Cervical Ripening Drugs Market – Taxonomy
2.2. Global Cervical Ripening Drugs Market –Definitions
2.2.1. Drug class
2.2.2. Distribution Channel
3. GLOBAL CERVICAL RIPENING DRUGS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cervical Ripening Drugs Market Dynamics – Factors Impact Analysis
3.6. Global Cervical Ripening Drugs Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Cervical Ripening Drugs Market – Product Innovations
4. GLOBAL CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL CERVICAL RIPENING DRUGS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Drug Class Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Prostaglandins
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Oxytocin
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. Progesterone Receptor Antagonists
5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.1.4. Relaxin
5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.4.3. Market Opportunity Analysis
5.1.5. Estrogen
5.1.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.5.3. Market Opportunity Analysis
5.1.6. Others
5.1.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.6.3. Market Opportunity Analysis
6. GLOBAL CERVICAL RIPENING DRUGS MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1.1. Oral
6.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.1.3. Market Opportunity Analysis
6.1.2. Intravenous
6.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.2.3. Market Opportunity Analysis
6.2. Vaginal
6.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.1.3. Market Opportunity Analysis
7. MARKET OPPORTUNITY ANALYSIS GLOBAL CERVICAL RIPENING DRUGS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. GLOBAL CERVICAL RIPENING DRUGS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Diseases Type, Distribution Channel, and Region, 2017 – 2023
9. NORTH AMERICA CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Prostaglandins
9.1.1.2. Oxytocin
9.1.1.3. Progesterone Receptor Antagonists
9.1.1.4. Relaxin
9.1.1.5. Estrogen
9.1.1.6. Others
9.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Oral
9.1.2.2. Intravenous
9.1.2.3. Vaginal
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel and Country, 2017 – 2023
9.1.6. North America Cervical Ripening Drugs Market Dynamics – Trends
10. EUROPE CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2.1. Prostaglandins
10.1.2.2. Oxytocin
10.1.2.3. Progesterone Receptor Antagonists
10.1.2.4. Relaxin
10.1.2.5. Estrogen
10.1.2.6. Others
10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Oral
10.1.3.2. Intravenous
10.1.3.3. Vaginal
10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Hospital Pharmacies
10.1.4.2. Retail Pharmacies
10.1.4.3. Others
10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.5.1. Germany
10.1.5.2. UK
10.1.5.3. France
10.1.5.4. Spain
10.1.5.5. Italy
10.1.5.6. Russia
10.1.5.7. Poland
10.1.5.8. Rest of Europe
10.1.6. Europe Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
10.1.7. Europe Cervical Ripening Drugs Market Dynamics – Trends
11. ASIA-PACIFIC CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2.1. Prostaglandins
11.1.2.2. Oxytocin
11.1.2.3. Progesterone Receptor Antagonists
11.1.2.4. Relaxin
11.1.2.5. Estrogen
11.1.2.6. Others
11.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Oral
11.1.3.2. Intravenous
11.1.3.3. Vaginal
11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.4.1. Hospital Pharmacies
11.1.4.2. Retail Pharmacies
11.1.4.3. Others
11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.5.1. Japan
11.1.5.2. China
11.1.5.3. India
11.1.5.4. ASEAN
11.1.5.5. Australia & New Zealand
11.1.5.6. Rest of Asia-Pacific
11.1.6. Asia-Pacific Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
11.1.7. Europe Cervical Ripening Drugs Market Dynamics – Trends
12. LATIN AMERICA CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2.1. Prostaglandins
12.1.2.2. Oxytocin
12.1.2.3. Progesterone Receptor Antagonists
12.1.2.4. Relaxin
12.1.2.5. Estrogen
12.1.2.6. Others
12.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Oral
12.1.3.2. Intravenous
12.1.3.3. Vaginal
12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Hospital Pharmacies
12.1.4.2. Retail Pharmacies
12.1.4.3. Others
12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.5.1. Brazil
12.1.5.2. Mexico
12.1.5.3. Argentina
12.1.5.4. Venezuela
12.1.5.5. Rest of Latin America
12.1.6. Latin America Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
12.1.7. Latin America Cervical Ripening Drugs Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.2. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.2.1. Prostaglandins
13.1.2.2. Oxytocin
13.1.2.3. Progesterone Receptor Antagonists
13.1.2.4. Relaxin
13.1.2.5. Estrogen
13.1.2.6. Others
13.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Oral
13.1.3.2. Intravenous
13.1.3.3. Vaginal
13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.4.1. Hospital Pharmacies
13.1.4.2. Retail Pharmacies
13.1.4.3. Others
13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.5.1. Gulf Cooperation Council (GCC) Countries
13.1.5.2. Israel
13.1.5.3. South Africa
13.1.5.4. Rest of MEA
13.1.6. MEA Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
13.1.7. MEA Cervical Ripening Drugs Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Ferring B.V. (Switzerland)
14.2.2. Azanta A/S (Denmark)
14.2.3. Novartis AG (Switzerland)
14.2.4. GlaxoSmithKline plc (U.K.)
14.2.5. AstraZeneca plc (U.K.)
14.2.6. Pfizer, Inc. (U.S.)
14.2.7. Bayer AG (Germany)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL CERVICAL RIPENING DRUGS MARKET INTRODUCTION
2.1. Global Cervical Ripening Drugs Market – Taxonomy
2.2. Global Cervical Ripening Drugs Market –Definitions
2.2.1. Drug class
2.2.2. Distribution Channel
3. GLOBAL CERVICAL RIPENING DRUGS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cervical Ripening Drugs Market Dynamics – Factors Impact Analysis
3.6. Global Cervical Ripening Drugs Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Cervical Ripening Drugs Market – Product Innovations
4. GLOBAL CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL CERVICAL RIPENING DRUGS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Drug Class Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Prostaglandins
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Oxytocin
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. Progesterone Receptor Antagonists
5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.1.4. Relaxin
5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.4.3. Market Opportunity Analysis
5.1.5. Estrogen
5.1.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.5.3. Market Opportunity Analysis
5.1.6. Others
5.1.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.6.3. Market Opportunity Analysis
6. GLOBAL CERVICAL RIPENING DRUGS MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1.1. Oral
6.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.1.3. Market Opportunity Analysis
6.1.2. Intravenous
6.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.2.3. Market Opportunity Analysis
6.2. Vaginal
6.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.1.3. Market Opportunity Analysis
7. MARKET OPPORTUNITY ANALYSIS GLOBAL CERVICAL RIPENING DRUGS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. GLOBAL CERVICAL RIPENING DRUGS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Diseases Type, Distribution Channel, and Region, 2017 – 2023
9. NORTH AMERICA CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Prostaglandins
9.1.1.2. Oxytocin
9.1.1.3. Progesterone Receptor Antagonists
9.1.1.4. Relaxin
9.1.1.5. Estrogen
9.1.1.6. Others
9.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Oral
9.1.2.2. Intravenous
9.1.2.3. Vaginal
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel and Country, 2017 – 2023
9.1.6. North America Cervical Ripening Drugs Market Dynamics – Trends
10. EUROPE CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2.1. Prostaglandins
10.1.2.2. Oxytocin
10.1.2.3. Progesterone Receptor Antagonists
10.1.2.4. Relaxin
10.1.2.5. Estrogen
10.1.2.6. Others
10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Oral
10.1.3.2. Intravenous
10.1.3.3. Vaginal
10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Hospital Pharmacies
10.1.4.2. Retail Pharmacies
10.1.4.3. Others
10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.5.1. Germany
10.1.5.2. UK
10.1.5.3. France
10.1.5.4. Spain
10.1.5.5. Italy
10.1.5.6. Russia
10.1.5.7. Poland
10.1.5.8. Rest of Europe
10.1.6. Europe Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
10.1.7. Europe Cervical Ripening Drugs Market Dynamics – Trends
11. ASIA-PACIFIC CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2.1. Prostaglandins
11.1.2.2. Oxytocin
11.1.2.3. Progesterone Receptor Antagonists
11.1.2.4. Relaxin
11.1.2.5. Estrogen
11.1.2.6. Others
11.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Oral
11.1.3.2. Intravenous
11.1.3.3. Vaginal
11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.4.1. Hospital Pharmacies
11.1.4.2. Retail Pharmacies
11.1.4.3. Others
11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.5.1. Japan
11.1.5.2. China
11.1.5.3. India
11.1.5.4. ASEAN
11.1.5.5. Australia & New Zealand
11.1.5.6. Rest of Asia-Pacific
11.1.6. Asia-Pacific Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
11.1.7. Europe Cervical Ripening Drugs Market Dynamics – Trends
12. LATIN AMERICA CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2.1. Prostaglandins
12.1.2.2. Oxytocin
12.1.2.3. Progesterone Receptor Antagonists
12.1.2.4. Relaxin
12.1.2.5. Estrogen
12.1.2.6. Others
12.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Oral
12.1.3.2. Intravenous
12.1.3.3. Vaginal
12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Hospital Pharmacies
12.1.4.2. Retail Pharmacies
12.1.4.3. Others
12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.5.1. Brazil
12.1.5.2. Mexico
12.1.5.3. Argentina
12.1.5.4. Venezuela
12.1.5.5. Rest of Latin America
12.1.6. Latin America Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
12.1.7. Latin America Cervical Ripening Drugs Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA CERVICAL RIPENING DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.2. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.2.1. Prostaglandins
13.1.2.2. Oxytocin
13.1.2.3. Progesterone Receptor Antagonists
13.1.2.4. Relaxin
13.1.2.5. Estrogen
13.1.2.6. Others
13.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Oral
13.1.3.2. Intravenous
13.1.3.3. Vaginal
13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.4.1. Hospital Pharmacies
13.1.4.2. Retail Pharmacies
13.1.4.3. Others
13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.5.1. Gulf Cooperation Council (GCC) Countries
13.1.5.2. Israel
13.1.5.3. South Africa
13.1.5.4. Rest of MEA
13.1.6. MEA Cervical Ripening Drugs Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
13.1.7. MEA Cervical Ripening Drugs Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Ferring B.V. (Switzerland)
14.2.2. Azanta A/S (Denmark)
14.2.3. Novartis AG (Switzerland)
14.2.4. GlaxoSmithKline plc (U.K.)
14.2.5. AstraZeneca plc (U.K.)
14.2.6. Pfizer, Inc. (U.S.)
14.2.7. Bayer AG (Germany)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
